Muscle News and Research

RSS

Anesthesia drug shortages can have devastating impact on patient care

The United States is facing ongoing shortages of several critical anesthesia medications—shortages with potentially serious effects on patient care and safety, according to a special article in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Nov 2011

Scientists identify MEGF10 defective gene responsible for muscle weakness

An international team of researchers from England and the Charité - Universitätsmedizin Berlin has presented new findings regarding the function of muscle stem cells, which are published in the current issue of the journal Nature Genetics.

23 Nov 2011

Asymmetric prototypes for mitral valve replacement

The heart's valves, which guarantee the unidirectional flow of blood from one chamber to another, are asymmetrical. For example, the two flaps of the heart's mitral valve - which regulates blood flow between the left atrium and the left ventricle - vary in size by up to 70 percent.

23 Nov 2011

Loyola expert shares symptoms, treatment of minor football injuries

Whether tackle or touch the traditional pick-up family football game is almost as important as the Thanksgiving dinner itself to many families.

23 Nov 2011

UCF researchers use stem cells to create nerve-muscle junctions

University of Central Florida researchers, for the first time, have used stem cells to grow neuromuscular junctions between human muscle cells and human spinal cord cells, the key connectors used by the brain to communicate and control muscles in the body.

23 Nov 2011

Men less willing to participate in cancer screening than women

Although men have higher cancer mortality rates than women, they are less willing to be screened for cancer, according to a study conducted by researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Sanoa Consulting LLC, Muscle Shoals, Ala., and the New York University College of Dentistry.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

New device safe, more effective for patients with chronic neurological conditions

Functional electrical stimulation (FES) was developed to help return lost function to patients with upper and lower extremity injuries and spinal cord injuries, among other applications. However, the devices, which work by stimulating neuronal activity in nerve-damaged patients, have a potential shortcoming in that the electrical currents needed for the treatment to work can also send errant signals to surrounding nerves, resulting in painful side effects.

22 Nov 2011

Researchers identify EGFR protein as therapeutic target for Cushing disease

Cushing disease is a hormone disorder that causes a diverse array of symptoms, including fat accumulation, high blood pressure, osteoporosis, muscle wasting, and ultimately death. It is caused by a tumor in the anterior pituitary gland that results in the secretion of excess amounts of adrenocorticotropic hormone (ACTH). Treatment options are essentially limited to surgical resection. However, tumors commonly recur, meaning that new treatment options are needed.

22 Nov 2011

Scientists discover second faulty gene linked to ALS

Following a major Northwestern Medicine breakthrough that identified a common converging point for all forms of amyotrophic lateral sclerosis (ALS and Lou Gehrig's disease), a new finding from the same scientists further broadens the understanding of why cells in the brain and spinal cord degenerate in the fatal disease.

21 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

MedUni Vienna researchers discover important regulators in development of stem cells

A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.

21 Nov 2011

Promising results from dexpramipexole phase 2 trial on ALS

Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.

20 Nov 2011

Researchers discover more about function of muscle stem cells

An international team of researchers from Leeds, London and Berlin has discovered more about the function of muscle stem cells, thanks to next-generation DNA sequencing techniques.

20 Nov 2011

New, incision-free surgery to manage chronic acid reflux

Adam Vasser would wake up at night choking on partially digested food and liquid. Stomach acid burned the delicate tissue of his throat. "I'd sleep really badly," he said. During the day, he sometimes suffered from heartburn.

19 Nov 2011

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

The U.S. Food and Drug Administration today approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL.

18 Nov 2011

Tonix to initiate TNX-102 PK and BA study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.

18 Nov 2011

HVTN debunks top 10 myths about HIV vaccine research

Dec. 1 is World AIDS Day, and in commemoration of the occasion, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, debunks the top 10 myths about HIV vaccine research.

18 Nov 2011

Simple roundworm may serve as ideal skin wound healing lab model

The lowly and simple roundworm may be the ideal laboratory model to learn more about the complex processes involved in repairing wounds and could eventually allow scientists to improve the body's response to healing skin wounds, a serious problem in diabetics and the elderly.

18 Nov 2011